Important notice

Warning – Fraudulent Calls

Several persons have received fraudulent calls impersonating RAMQ. If you do not have a pending request with us or if the call seems suspicious, do not provide any personal information. Make a note of the agent’s name, end the conversation and call us. To find out more, refer to Our communication practices webpage.

Gouvernement du Québec
Régie de l’assurance maladie

Important information

The contents of this webpage are in French only.

Find out whether a drug is covered

Over 8,000 prescription drugs are covered under the Public Prescription Drug Insurance Plan. They are included on a regularly updated list. Other drugs not on the list may also be covered on an exceptional basis.

Prescription drug search

Disclaimer : Search results do not have the same value as a legal document. To access the relevant legal document, please refer to the List of Medications.

4857 results found.

Example of search result explained

Taro-Tofacitinib XR

Exceptional medication
  • Active ingredient(s):
    tofacitinib citrate
  • Manufactured by:
    Taro Pharmaceuticals Inc. (Taro)
  • Strength and dosage form:
    Long-Action Tablet 11 mg DIN : 2553988

Steqeyma

Exceptional medication
  • Active ingredient(s):
    ustekinumab (ulcerative colitis and Crohn's disease)
  • Manufactured by:
    Celltrion Healthcare Canada Limited (Celltrion)
  • Strength and dosage form:
    • Subcutaneous Injectable Solution syringe 45 mg/0.5 mL DIN : 99114386
    • Subcutaneous Injectable Solution syringe 90 mg/1 mL DIN : 99114387
    • Intravenous Perfusion Solution 5 mg/mL (26 mL) DIN : 2550261
    • Subcutaneous Injectable Solution 45 mg/0.5 mL DIN : 99114512

Wezlana

Exceptional medication
  • Active ingredient(s):
    ustekinumab (plaque psoriasis children)
  • Manufactured by:
    Amgen Canada Inc. (Amgen)
  • Strength and dosage form:
    • Subcutaneous Injectable Solution syringe 45 mg/0.5 mL DIN : 99114450
    • Subcutaneous Injectable Solution syringe 90 mg/1 mL DIN : 99114448
    • Subcutaneous Injectable Solution 45 mg/0.5 mL DIN : 99114447
    • Subcutaneous Injectable Solution (pen) 45 mg/0.5 mL DIN : 99114445
    • Subcutaneous Injectable Solution (pen) 90 mg/1 mL DIN : 99114446

Hulio (syringe)

Exceptional medication
  • Active ingredient(s):
    adalimumab
  • Manufactured by:
    Biocon Biologics Canada Inc. (Biocon)
  • Strength and dosage form:
    • Subcutaneous Injectable Solution 50 mg/mL (0,4 mL) DIN : 2502380
    • Subcutaneous Injectable Solution 50 mg/mL (0.8 mL) DIN : 2502399

Hulio (pen)

Exceptional medication
  • Active ingredient(s):
    adalimumab
  • Manufactured by:
    Biocon Biologics Canada Inc. (Biocon)
  • Strength and dosage form:
    Subcutaneous Injectable Solution 50 mg/mL (0.8 mL) DIN : 2502402

Hulio (syringe)

Exceptional medication
  • Active ingredient(s):
    adalimumab (ulcerative colitis-children)
  • Manufactured by:
    Biocon Biologics Canada Inc. (Biocon)
  • Strength and dosage form:
    • Subcutaneous Injectable Solution 50 mg/mL (0,4 mL) DIN : 99114162
    • Subcutaneous Injectable Solution 50 mg/mL (0.8 mL) DIN : 99114161

Hulio (pen)

Exceptional medication
  • Active ingredient(s):
    adalimumab (ulcerative colitis-children)
  • Manufactured by:
    Biocon Biologics Canada Inc. (Biocon)
  • Strength and dosage form:
    Subcutaneous Injectable Solution 50 mg/mL (0.8 mL) DIN : 99114163

Hulio (syringe)

Exceptional medication
  • Active ingredient(s):
    adalimumab (hidradenitis suppurativa)
  • Manufactured by:
    Biocon Biologics Canada Inc. (Biocon)
  • Strength and dosage form:
    • Subcutaneous Injectable Solution 50 mg/mL (0,4 mL) DIN : 99114041
    • Subcutaneous Injectable Solution 50 mg/mL (0.8 mL) DIN : 99114042

Hulio (pen)

Exceptional medication
  • Active ingredient(s):
    adalimumab (hidradenitis suppurativa)
  • Manufactured by:
    Biocon Biologics Canada Inc. (Biocon)
  • Strength and dosage form:
    Subcutaneous Injectable Solution 50 mg/mL (0.8 mL) DIN : 99114043

Hulio (syringe)

Exceptional medication
  • Active ingredient(s):
    adalimumab (uveitis)
  • Manufactured by:
    Biocon Biologics Canada Inc. (Biocon)
  • Strength and dosage form:
    • Subcutaneous Injectable Solution 50 mg/mL (0,4 mL) DIN : 99114104
    • Subcutaneous Injectable Solution 50 mg/mL (0.8 mL) DIN : 99114105
Page 137 of 486

How did we do?

Was the information on this page useful to you?
Do not include any personal information. You will not receive any reply.